Coca-Cola (NYSE:KO) is not seeing the huge effect from GLP-1 usage that some investors feared when the drugs became more ...

First-of-its-kind integration introduces DNA-based supplement planning to telehealth-positioning DirectMeds as the leader in data-driven, outcome-focused virtual care. SALT LAKE C ...

Although coverage restrictions remain in place, the trendiness of weight loss drugs may be creating a growing cost concern ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. Eli Lilly is ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry’s growing pipeline of programs that are differentiated by the frequency of ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes.

A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE: LLY) entered into a collaboration and license agreement.

That’s up from a rate of 9.9 prescriptions per 100,000 in 2023, the first full year that Wegovy was available to children ...